EVOLUTION RMS 2 · MS200527_0082
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. EudraCT 2019-004980-36
Sponsor: MERCK
Phase: III
Area: Neuroimmunology